NeXT Personal Dx
Use
NeXT Personal Dx is a tumor-informed molecular residual disease (MRD) liquid biopsy designed for ultra-high sensitivity and specificity in detecting ctDNA. It is used to monitor patients with solid tumors to provide early insights into cancer recurrence and treatment efficacy. The test achieves industry-leading performance by leveraging whole-genome sequencing (WGS) and personalized signatures based on up to 1800 variants, empowering earlier cancer care interventions.
Special Instructions
Not provided.
Limitations
The test is not suitable for blood cancers such as leukemia and lymphomas. NeXT Personal Dx complements imaging but does not replace traditional cancer screening methods like mammograms or colonoscopies. Its performance characteristics have been determined by the Personalis Clinical Laboratory but it has not been FDA cleared or approved.
Methodology
NGS (WGS)
Biomarkers
No genes
Gene
Result Turnaround Time
28-35 days
Related Documents
For more information, please review the documents below
Specimen
Plasma
Volume
Not provided
Minimum Volume
Not provided
Container
2 Streck tubes
Collection Instructions
Two plasma tubes are required for follow-up tests.